Camp4 Therapeutics CORP Schedule 13G passive stakes

Balyasny Asset Management L.P. and affiliated entities have filed an amendment to their Schedule 13G, reporting beneficial ownership of 4.99% of Camp4 Therapeutics Corp. common stock.

Trails Edge Capital Partners, LP, along with affiliated entities, has reported beneficial ownership of approximately 6% of Camp4 Therapeutics Corp.'s common stock as of August 3, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.07% of Camp4 Therapeutics Corp. common stock as of March 31, 2026.

Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed a combined beneficial ownership of 7.4% in Camp4 Therapeutics Corp, as reported in a Schedule 13G filing.

FMR LLC and Abigail P. Johnson have reported a 9.5% beneficial ownership stake in CAMP4 Therapeutics Corporation as of December 31, 2025.

Janus Henderson Group plc has reported a 12.2% beneficial ownership stake in CAMP4 THERAPEUTICS CORP, as detailed in a recent Schedule 13G filing.

Coastlands Capital LP filed an amendment to its Schedule 13G for Camp4 Therapeutics Corp, correcting a rounding error in its reported 9.99% beneficial ownership.

AH Bio Funds and managing members Marc Andreessen and Benjamin Horowitz report beneficial ownership of 4.5% of CAMP4 THERAPEUTICS CORPORATION common stock.

Northpond Ventures entities and Michael P. Rubin have filed an amended Schedule 13G, disclosing their beneficial ownership in CAMP4 THERAPEUTICS CORPORATION as of September 30, 2025.

FMR LLC and Abigail P. Johnson have disclosed a 6.7% beneficial ownership stake in CAMP4 Therapeutics Corporation, held in the ordinary course of business.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in CAMP4 Therapeutics Corp. common stock as of September 30, 2025.

HarbourVest Partners and affiliated entities reported a 2.7% beneficial ownership stake in CAMP4 Therapeutics Corporation, totaling 1,271,948 shares.

Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. have disclosed beneficial ownership of 8.4% of Camp4 Therapeutics Corp's common stock following a private placement.

Coastlands Capital and its affiliates have disclosed a 9.99% beneficial ownership stake in Camp4 Therapeutics Corp, following a recent private placement.

HarbourVest Partners and its affiliated entities have disclosed a passive beneficial ownership of 6.3% in CAMP4 Therapeutics Corporation, totaling 1,271,948 shares of common stock.